{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:12:24Z","timestamp":1790140344399,"version":"4.0.1"},"reference-count":25,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Nearly one-third of individuals with metabolic dysfunction\u2013associated steatotic liver disease (MASLD)\/non-alcoholic fatty liver disease (NAFLD) are non-obese, yet evidence for pharmacotherapy in this subgroup remains limited. This study assessed the safety and effectiveness of saroglitazar among non-obese individuals with MASLD\/NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this open-label randomised controlled trial (RCT), non-obese [body mass index (BMI) &lt;25 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ] adults with NAFLD\/MASLD and raised alanine aminotransferase levels (ALT &gt;50 U\/L) were allocated in a 1:1 ratio to either saroglitazar (4 mg\/day) combined with lifestyle modification (Group A) or lifestyle intervention alone (Group B) for a period of six months. The trial was registered with clinical trial registry (CTRI\/2022\/09\/046081). The primary outcome was the change in controlled attenuation parameter (CAP). Secondary outcomes included changes in anthropometric measures, insulin resistance, glycaemic indices, lipid profile, ALT, fibroscan\u2013aspartate aminotransferase (FAST) score, hepatic steatosis index (HSI), non-invasive fibrosis markers [liver stiffness measurement (LSM), fibrosis-4 (FIB-4), aspartate aminotransferase to platelet ratio index (APRI),], and adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-six participants (33 per group) completed the study. Both groups showed significant reductions in CAP; however, the median change in CAP did not differ between the two groups [24 dB\/m (9\u201348.8)\n                      <jats:italic>vs.<\/jats:italic>\n                      14 dB\/m (\u22124.5 to 50);\n                      <jats:italic>P<\/jats:italic>\n                      =0.52]. Alterations in BMI and waist circumference were similar between groups. Homeostasis model assessment-estimated insulin resistance (HOMA-IR) [0.68 (0.14\u20131.69)\n                      <jats:italic>vs<\/jats:italic>\n                      . \u22120.51 (\u22121.12 to 0.44);\n                      <jats:italic>P<\/jats:italic>\n                      =0.03], triglycerides [34 (\u22121.5 to 76.8)\n                      <jats:italic>vs<\/jats:italic>\n                      . \u221210 (\u221228.5 to 20.5) mg\/dL;\n                      <jats:italic>P<\/jats:italic>\n                      =0.006], and ALT (43.7\u00b136.7\n                      <jats:italic>vs<\/jats:italic>\n                      . 28.1\u00b121.5 U\/L;\n                      <jats:italic>P<\/jats:italic>\n                      =0.04) were significantly improved in the saroglitazar group. Changes in HSI, FAST score, APRI, FIB-4, and liver stiffness were similar between groups. No serious adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation and conclusions<\/jats:title>\n                    <jats:p>In non-obese NAFLD\/MASLD patients, the combination of saroglitazar with lifestyle changes over a period of six months improved insulin resistance, triglycerides, and ALT but did not confer additional benefit over lifestyle intervention alone for non-invasive hepatic steatosis or liver fibrosis markers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.25259\/ijmr_2953_2025","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:06:09Z","timestamp":1777359969000},"page":"477-485","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial"],"prefix":"10.25259","volume":"163","author":[{"given":"Naveen","family":"Bhagat","sequence":"first","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arka","family":"De","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Duseja","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"C.P.","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Taneja","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Sahni","sequence":"additional","affiliation":[{"name":"Department of Dietetics, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virendra","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"10.25259\/IJMR_2953_2025\/ref-1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.25259\/IJMR_2953_2025\/ref-2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/cld.1141","article-title":"Nonalcoholic fatty liver disease: Indian perspective","volume":"18","author":"De","year":"2021","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"10.25259\/IJMR_2953_2025\/ref-3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.25259\/IJMR_2953_2025\/ref-5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/joim.13069","article-title":"Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016","volume":"288","author":"Zou","year":"2020","journal-title":"J Intern Med."},{"key":"10.25259\/IJMR_2953_2025\/ref-6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.clnu.2018.08.008","article-title":"Lean non-alcoholic fatty liver disease","volume":"38","author":"Wang","year":"2019","journal-title":"Clin Nutr."},{"key":"10.25259\/IJMR_2953_2025\/ref-7","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/liv.15674","article-title":"The NAFLD burden on mortality and morbidities in general population: A community-based longitudinal study (NASH-CO study)","volume":"43","author":"Nabi","year":"2023","journal-title":"Liver Int."},{"key":"10.25259\/IJMR_2953_2025\/ref-8","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.cgh.2022.11.019","article-title":"Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"21","author":"Ha","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.25259\/IJMR_2953_2025\/ref-9","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/postmj\/qgad035","article-title":"Impact of body mass index on disease progression and outcomes in patients with nonalcoholic fatty liver disease","volume":"99","author":"Biswas","year":"2023","journal-title":"Postgrad Med J."},{"key":"10.25259\/IJMR_2953_2025\/ref-10","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41366-023-01346-w","article-title":"Lean indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD","volume":"47","author":"De","year":"2023","journal-title":"Int J Obes (Lond)."},{"key":"10.25259\/IJMR_2953_2025\/ref-11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian national association for study of the liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD)","volume":"13","author":"Duseja","year":"2023","journal-title":"J Clin Exp Hepatol."},{"key":"10.25259\/IJMR_2953_2025\/ref-12","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology."},{"key":"10.25259\/IJMR_2953_2025\/ref-13","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2016","journal-title":"J Hepatol Elsevier."},{"key":"10.25259\/IJMR_2953_2025\/ref-14","doi-asserted-by":"publisher","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: A prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep."},{"key":"10.25259\/IJMR_2953_2025\/ref-15","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.25259\/IJMR_2953_2025\/ref-16","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: A randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology."},{"key":"10.25259\/IJMR_2953_2025\/ref-17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol."},{"key":"10.25259\/IJMR_2953_2025\/ref-18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jhep.2013.12.018","article-title":"Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations","volume":"60","author":"De L\u00e9dinghen","year":"2014","journal-title":"J Hepatol."},{"key":"10.25259\/IJMR_2953_2025\/ref-19","doi-asserted-by":"publisher","first-page":"e00136","DOI":"10.1002\/prp2.136","article-title":"Saroglitazar, a novel PPAR\u03b1\/\u03b3 agonist with predominant PPAR\u03b1 activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models","volume":"3","author":"Jain","year":"2015","journal-title":"Pharmacol Res Perspect."},{"key":"10.25259\/IJMR_2953_2025\/ref-20","doi-asserted-by":"publisher","first-page":"113127","DOI":"10.1016\/j.biopha.2022.113127","article-title":"Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease","volume":"151","author":"Pan","year":"2022","journal-title":"Biomed Pharmacother."},{"key":"10.25259\/IJMR_2953_2025\/ref-21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience","volume":"7","author":"Chaudhuri","year":"2023","journal-title":"JGH Open."},{"key":"10.25259\/IJMR_2953_2025\/ref-22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jceh.2021.03.012","article-title":"Safety and efficacy of saroglitazar in nonalcoholic fatty liver patients with diabetic dyslipidemia-a prospective, interventional, pilot study","volume":"12","author":"Rajesh","year":"2022","journal-title":"J Clin Exp Hepatol."},{"key":"10.25259\/IJMR_2953_2025\/ref-23","doi-asserted-by":"publisher","first-page":"e9065","DOI":"10.7759\/cureus.9065","article-title":"An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Mitra","year":"2020","journal-title":"Cureus."},{"key":"10.25259\/IJMR_2953_2025\/ref-24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for nonalcoholic fatty liver disease: A single centre experience in 91 patients","volume":"12","author":"Padole","year":"2022","journal-title":"J Clin Exp Hepatol."},{"key":"10.25259\/IJMR_2953_2025\/ref-25","doi-asserted-by":"crossref","first-page":"e4287075","DOI":"10.1155\/2020\/4287075","article-title":"Clinical case series of decrease in shear wave elastography values in ten diabetic dyslipidemia patients having NAFLD with saroglitazar 4 mg: An indian experience","volume":"2020","author":"Roy","year":"2020","journal-title":"Case Rep Med."},{"key":"10.25259\/IJMR_2953_2025\/ref-26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA Clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology."}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/saroglitazar-for-non-obese-metabolic-dysfunction-associated-steatotic-liver-disease-masld-an-open-label-randomised-controlled-trial\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/saroglitazar-for-non-obese-metabolic-dysfunction-associated-steatotic-liver-disease-masld-an-open-label-randomised-controlled-trial\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:06:10Z","timestamp":1777359970000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/saroglitazar-for-non-obese-metabolic-dysfunction-associated-steatotic-liver-disease-masld-an-open-label-randomised-controlled-trial\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":25,"alternative-id":["10.25259\/IJMR_2953_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_2953_2025","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"477"}}